
A study assessed the efficacy and safety of renal denervation (RDN) in patients with hypertension on triple antihypertensive therapy. In this study, involving 217 patients, RDN led to a significant reduction in 24-hour ambulatory systolic blood pressure (−13.0±12.1 mm Hg) compared to the sham group (−3.0±13.0 mm Hg), with a baseline-adjusted between-group difference of −9.4 mm Hg (95% confidence interval [CI]: −12.8 to −5.9; p<0.001). Diastolic blood pressure also decreased more in the RDN group (−5.0 mm Hg; 95% CI: −7.5 to −2.4; p<0.001). Office blood pressure reductions were similarly significant. Only one patient experienced a minor complication. RDN proved both effective and safe in reducing blood pressure in this cohort of Chinese patients.
Like
Save
Share